• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Acucela receives 'Emerging Leader' award

Article

Acucela Inc. has been named as a recipient of the 2012 Emerging Leaders award from the Japan-U.S. Innovation Awards

Seattle-Acucela Inc. has been named as a recipient of the 2012 Emerging Leaders award from the Japan-U.S. Innovation Awards.

Acucela is a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases.

Now in its second year, the Japan-U.S. Innovation Awards program is sponsored by the Japan Society of Northern California in collaboration with the Stanford University U.S.-Asia Technology Management Center. The awards are designed to recognize the synergy between Japan and the United States by honoring outstanding companies from both countries that have achieved highly noteworthy innovation in their business or technology.

The Emerging Leaders award highlights two companies-one from Japan and one from the United States-that are young, small, dynamic, growing, entrepreneurial, and have a credible footprint in both Japan and the United States.

“It is an honor to accept this award on behalf of Acucela, and a testament to the important work our entire team contributes every day to continue the fight against blinding eye diseases,” said Ryo Kubota, MD, PhD, Acucela’s chairman, president, and chief executive officer.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.